Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2015 Apr 28;112(9):1445-51.
doi: 10.1038/bjc.2015.127. Epub 2015 Apr 16.

Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?

D J A Lobbezoo  1 , R J W van Kampen  2 , A C Voogd  3 , M W Dercksen  4 , F van den Berkmortel  5 , T J Smilde  6 , A J van de Wouw  7 , F P J Peters  8 , J M G H van Riel  9 , N A J B Peters  10 , M de Boer  2 , P G M Peer  11 , V C G Tjan-Heijnen  2
Affiliations
Comparative Study

Prognosis of metastatic breast cancer: are there differences between patients with de novo and recurrent metastatic breast cancer?

D J A Lobbezoo et al. Br J Cancer. .

Abstract

Background: We aimed to determine the prognostic impact of time between primary breast cancer and diagnosis of distant metastasis (metastatic-free interval, MFI) on the survival of metastatic breast cancer patients.

Methods: Consecutive patients diagnosed with metastatic breast cancer in 2007-2009 in eight hospitals in the Southeast of the Netherlands were included and categorised based on MFI. Survival curves were estimated using the Kaplan-Meier method. Cox proportional hazards model was used to determine the prognostic impact of de novo metastatic breast cancer vs recurrent metastatic breast cancer (MFI ⩽24 months and >24 months), adjusted for age, hormone receptor and HER2 status, initial site of metastasis and use of prior (neo)adjuvant systemic therapy.

Results: Eight hundred and fifteen patients were included and divided in three subgroups based on MFI; 154 patients with de novo metastatic breast cancer, 176 patients with MFI <24 months and 485 patients with MFI >24 months. Patients with de novo metastatic breast cancer had a prolonged survival compared with patients with recurrent metastatic breast cancer with MFI <24 months (median 29.4 vs 9.1 months, P<0.0001), but no difference in survival compared with patients with recurrent metastatic breast cancer with MFI >24 months (median, 29.4 vs 27.9 months, P=0.73). Adjusting for other prognostic factors, patients with MFI <24 months had increased mortality risk (hazard ratio 1.97, 95% CI 1.49-2.60, P<0.0001) compared with patients with de novo metastatic breast cancer. When comparing recurrent metastatic breast cancer with MFI >24 months with de novo metastatic breast cancer no significant difference in mortality risk was found. The association between MFI and survival was seen irrespective of use of (neo)adjuvant systemic therapy.

Conclusion: Patients with de novo metastatic breast cancer had a significantly better outcome when compared with patients with MFI <24 months, irrespective of the use of prior adjuvant systemic therapy in the latter group. However, compared with patients with MFI >24 months, patients with de novo metastatic breast cancer had similar outcome.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Survival after diagnosis of metastatic breast cancer for patients with de novo metastatic breast cancer and recurrent metastatic breast cancer with MFI <24 months and recurrent metastatic breast cancer with MFI >24 months.
See this image and copyright information in PMC

References

    1. Ali D, Le Scodan R. Treatment of the primary tumor in breast cancer patients with synchronous metastases. Ann Oncol. 2011;22:9–16. - PubMed
    1. Andre F, Slimane K, Bachelot T, Dunant A, Namer M, Barrelier A, Kabbaj O, Spano JP, Marsiglia H, Rouzier R, Delaloge S, Spielmann M. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol. 2004;22:3302–3308. - PubMed
    1. Badwe R, Parmar V, Hawaldar R, Nair N, Kaushik R, Siddique S, Navale A, Budrukkar A, Mittra I, Gupta S. Abstract S2-02: Surgical removal of primary tumor and axillary lymph nodes in women with metastatic breast cancer at first presentation: A randomized controlled trial. Cancer Res. 2013;73:S2–02-S2-02.
    1. Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, Francis P, Gligorov J, Kyriakides S, Lin N, Pagani O, Senkus E, Thomssen C, Aapro M, Bergh J, Di Leo A, El Saghir N, Ganz PA, Gelmon K, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Leadbeater M, Mayer M, Rodger A, Rugo H, Sacchini V, Sledge G, van't Veer L, Viale G, Krop I, Winer E. 1st International consensus guidelines for advanced breast cancer (ABC 1) Breast. 2012;21:242–252. - PubMed
    1. Chiang AC, Massague J. Molecular basis of metastasis. N Engl J Med. 2008;359:2814–2823. - PMC - PubMed

Publication types